Rice Partnership LLC Has $8.38 Million Stake in Johnson & Johnson (NYSE:JNJ)

Rice Partnership LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,284 shares of the company’s stock after buying an additional 1,171 shares during the quarter. Johnson & Johnson comprises approximately 2.4% of Rice Partnership LLC’s investment portfolio, making the stock its 11th biggest holding. Rice Partnership LLC’s holdings in Johnson & Johnson were worth $8,380,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. GQG Partners LLC lifted its position in shares of Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after purchasing an additional 3,627,424 shares in the last quarter. Vanguard Group Inc. raised its position in Johnson & Johnson by 1.4% during the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after acquiring an additional 3,358,478 shares in the last quarter. Finally, State Street Corp raised its position in Johnson & Johnson by 1.8% during the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Stock Up 0.8 %

Johnson & Johnson stock opened at $165.39 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The firm has a 50 day moving average price of $170.60 and a two-hundred day moving average price of $174.13. The firm has a market cap of $434.84 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 3.12 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the business earned $2.48 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a dividend of $1.13 per share. The ex-dividend date was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.73%. Johnson & Johnson’s payout ratio is 65.79%.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Citigroup dropped their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.